EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, United Therapeutics's enterprise value is $8,809 Mil.
United Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $2,328 Mil. Therefore, United Therapeutics's EV-to-Revenue for today is 3.78.
The historical rank and industry rank for United Therapeutics's EV-to-Revenue or its related term are showing as below:
UTHR'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.69 Med: 3.87 Max: 7.02
Current: 3.79
During the past 13 years, the highest EV-to-Revenue of United Therapeutics was 7.02. The lowest was 1.69. And the median was 3.87.
UTHR's EV-to-Revenue is ranked better than 66.02% of 1033
companies
in the Biotechnology industry
Industry Median: 7.68
vs UTHR: 3.79
The historical data trend for United Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of United Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, United Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, United Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where United Therapeutics's EV-to-Revenue falls into.
United Therapeutics's current Enterprise Value is $8,809 Mil.
United Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,328 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (NAS:UTHR) EV-to-Revenue Explanation
United Therapeutics's share price for today is $235.03.
United Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $46.83.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of United Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
United Therapeutics (United Therapeutics) Business Description
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
UTHR has been successfully added to your 